The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk

Citation:

Elenjickal EJ, Baroz F, Boileau P, et al. Diabetes Obes Metab. 2026 Aug;28(8):7083-7093. Epub 2026 May 31. PMID: 42219264; PMCID: PMC13341376.